SCHEMBL26653892

SCHEMBL26653892

Cn1c(C2(O)CCNCC2)cc2nnc(-c3ccccc3O)cc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMARCA2 P51531 12/20 0.43
▸ SMARCA4 P51532 12/20 0.43
▸ PBRM1 Q86U86 11/20 0.43
▸ NR1I2 O75469 9/20 0.36
▸ BRD4 O60885 1/20 0.36
▸ MAPT P10636 2/20 0.34
▸ HPGD P15428 2/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ RECQL P46063 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ NR1H2 P55055 3/20 0.33
▸ SIGMAR1 Q99720 1/20 0.33
▸ NR1H3 Q13133 3/20 0.33
▸ HSD11B1 P28845 1/20 0.33
▸ PDE10A Q9Y233 1/20 0.32
▸ USP2 O75604 1/20 0.32
▸ ALOX15 P16050 1/20 0.32
▸ TSHR P16473 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26653859 0.78 PBRM1 (0.55) SMARCA2SMARCA4PBRM1NR1I2BRD4
SCHEMBL26654170 0.78 SMARCA2 (0.55) SMARCA2SMARCA4PBRM1ALOX15TSHR
SCHEMBL26653819 0.77 PBRM1 (0.43) SMARCA2SMARCA4PBRM1NR1I2BRD4
SCHEMBL26653822 0.74 PDE10A (0.42) SMARCA2SMARCA4PBRM1NR1I2BRD4
SCHEMBL31294027 0.70 PBRM1 (0.39) SMARCA2SMARCA4PBRM1NR1I2BRD4
SCHEMBL23580581 0.68 SMARCA2 (0.48) SMARCA2SMARCA4PBRM1NR1I2BRD4
SCHEMBL30340773 0.68 SMARCA2 (0.48) SMARCA2SMARCA4PBRM1NR1I2BRD4
SCHEMBL31570184 0.68 PBRM1 (0.41) SMARCA2SMARCA4PBRM1NR1I2BRD4
SCHEMBL26685145 0.68 PBRM1 (0.41) SMARCA2SMARCA4PBRM1NR1I2BRD4
SCHEMBL26683624 0.68 PBRM1 (0.41) SMARCA2SMARCA4PBRM1NR1I2BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250302832-A1 PYRAZINE DERIVATIVES AND USES THEREOF FOGHORN THERAPEUTICS INC (US) 2025-10-02 — — US disclosed
EP-4522279-A1 PYRAZINE DERIVATIVES AND USES THEREOF Foghorn Therapeutics Inc. (US) 2025-03-19 — — EP disclosed
WO-2023220134-A1 PYRAZINE DERIVATIVES AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2023-11-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250302832-A1 PYRAZINE DERIVATIVES AND USES THEREOF BRCA1, VHL, SF3B5 SMARCA2 77/4885SMARCA4 19/4885PBRM1 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback